US 12,168,010 B2
Use of co-enzyme antagonists to slow metabolism
Johannes Coy, Hainburg (DE); and Ralf Schierl, Darmstadt-Eberstadt (DE)
Assigned to Tavargenix GmbH, Darmstadt (DE)
Appl. No. 18/010,816
Filed by Tavargenix GmbH, Darmstadt (DE)
PCT Filed Jun. 21, 2021, PCT No. PCT/DE2021/100528
§ 371(c)(1), (2) Date Dec. 16, 2022,
PCT Pub. No. WO2021/259423, PCT Pub. Date Dec. 30, 2021.
Claims priority of application No. 10 2020 116 980.9 (DE), filed on Jun. 27, 2020.
Prior Publication US 2023/0226060 A1, Jul. 20, 2023
Int. Cl. A61K 31/51 (2006.01); A61K 45/06 (2006.01); A61P 31/12 (2006.01); A61P 35/00 (2006.01)
CPC A61K 31/51 (2013.01) [A61K 45/06 (2013.01); A61P 31/12 (2018.01); A61P 35/00 (2018.01)] 18 Claims
 
1. A method for successively slowing anabolic, catabolic and/or energy-releasing metabolic processes of cells in the body of a patient suffering from cancer comprising:
administering as part of a tumor cell treatment of the patient suffering from cancer oxythiamine (OT) or benfooxythiamine (B-OT), wherein the OT or B-OT is administered in an amount effective to inhibit a thiamine-dependent enzyme to a target value, wherein the target value corresponds to an inhibition of an activity of the thiamine-dependent enzyme by at least 20% in the cells in the body of the patient, wherein the cells comprise healthy and tumor cells of the patient, wherein the administration comprises:
(i) administering the OT or B-OT in a first dose of a dosage regime,
(ii) subsequently monitoring an effect of the inhibition on the healthy cells of the patient,
(iii) adjusting, if desired, the target value based on (ii) and
(iv) administering in one or more consecutive doses of the dosage regime, the OT or B-OT in an amount effective to reach the target value of (iii) without irreversibly damaging the healthy cells of the patient and/or while maintaining basic functions of the body of the patient, and
(v) subsequently or concurrently administering a chemotherapy, radiotherapy and/or targeted cancer therapy to the patient.